Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: S&L, SO, Warrant Mess, Temoto and dotOB

Dec 11, 2006 05:07PM

Dec 11, 2006 06:15PM

Dec 12, 2006 10:25AM

Dec 12, 2006 11:22AM

Before all the debentures were converted S&L could not own more than 4.99% of the OS and therefore never filed a 13G with the SEC. I believe this was some kind of negotiated restriction between Patriot and S&L because the SEC doesn't limit anyone from buying more than 4.99% of any company. Now when the renegotiating took place to allow S&L to control up to but not more than 9.99% of the OS beneficially (that means together 4.99% + 4.99%) they quickly filed a 13G to disclose that they were now a > 5% owner. The SEC rule states that if any changes in the ownership (amounts or persons) are made then an amendment must be filed to the original 13G. How the hell they are getting around this I have no clue and I ask for anyones help! The problem with your theory is that S&L cannot claim to own 4.99% each because on the 13GĀ filing they state they own 9.99% beneficially combined. If they were separate entities (which they are not, they are related) then they would have never filed a 13G to begin with.

I am in finance but not this kind....the kind of stuff LG did with S&L is absurd. I'm just trying to untangle it all because I think this has and continues to be one of the most important reasons as to why our share price languishes even after 13 revenue producing deals in the last 18 months. You tell anyone about a profitable company that potentially has the whole chip industry by the balls selling for 60 cents and they would laugh at you in disbelief.


Dec 12, 2006 04:12PM

Dec 12, 2006 04:24PM

Dec 12, 2006 04:40PM

Dec 13, 2006 02:57AM

Dec 13, 2006 05:45AM

Dec 13, 2006 07:17AM

Dec 13, 2006 07:38AM

Dec 13, 2006 07:40AM

Dec 13, 2006 07:47AM

Dec 13, 2006 07:55AM
Share
New Message
Please login to post a reply